17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Targeting hydrogen sulphide signaling in breast cancer

      review-article
      a , b , c , d , e , c , d , f , g , h , g , h , i , i , j , k , b , c , d , e , l , m , *
      Journal of Advanced Research
      Elsevier
      Breast cancer, Hydrogen sulphide, miR-155/NOS2/NO signaling pathway, PI3K/AKT signaling pathway, Nitric oxide, miR-4317, Natural killer cells, CAR T cells, BC, Breast Cancer, CAR, Chimeric antigen receptor, 51Cr-release, Chromium release assay, CD80, Cluster of differentiation 80, CD86, Cluster of differentiation 86, CBS, Cystathionine β-synthase, CSE, Cystathionine γ-lyase, CTL, Cytotoxic T lymphocyte, NOS3, Endothelial nitric oxide synthase-3, HCC, Hepatocellular carcinoma, HLA-DR, Human Leukocytic antigen DR, H2S, Hydrogen sulphide, NOS2, Inducible nitric oxide synthase-2, IFN-γ, Interferon gamma, KD, Knock down, LDH, Lactate dehydrogenase Assay, MICA/B, MHC class I polypeptide-related sequence A/B, miRNA, MicroRNA, NKG2D, Natural Killer Group 2D , NK, Natural killer, NO, Nitric oxide, ncRNAs, Non-coding RNAs, PD-L1, Programmed death-ligand 1, Scr-miRNAs, Scrambled microRNAs, Scr-siRNAs, Scrambled siRNAs, siRNAs, Small interfering RNAs, TNBC, Triple negative breast cancer, TNF-α, Tumor necrosis factor-α, ULBP2/5/6, UL16 binding protein 2/5/6, 41BBL, 41BB Ligand

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Graphical abstract

          Abstract

          Introduction

          Hydrogen sulphide (H 2S) has been established as a key member of the gasotransmitters family that recently showed a pivotal role in various pathological conditions including cancer.

          Objectives

          This study investigated the role of H 2S in breast cancer (BC) pathogenesis, on BC immune recognition capacity and the consequence of targeting H 2S using non-coding RNAs.

          Methods

          Eighty BC patients have been recruited for the study. BC cell lines were cultured and transfected using validated oligonucleotide delivery system. Gene and protein expression analysis was performed using qRT-PCR, western blot and flow-cytometry. In-vitro analysis for BC hallmarks was performed using MTT, BrdU, Modified Boyden chamber, migration and colony forming assays. H 2S and nitric oxide (NO) levels were measured spectrophotometrically. Primary natural killer cells (NK cells) and T cell isolation and chimeric antigen receptor transduction (CAR T cells) were performed using appropriate kits. NK and T cells cytotoxicity was measured. Finally, computational target prediction analysis and binding confirmation analyses were performed using different software and dual luciferase assay kit, respectively.

          Results

          The H 2S synthesizing enzymes, cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE), exhibited elevated levels in the clinical samples that correlated with tumor proliferation index. Knock-down of CBS and CSE in the HER2+ BC and triple negative BC (TNBC) cells resulted in significant attenuation of BC malignancy. In addition to increased susceptibility of HER2+ BC and TNBC to the cytotoxic activity of HER2 targeting CAR T cells and NK cells, respectively. Transcriptomic and phosphoprotein analysis revealed that H 2S signaling is mediated through Akt in MCF7, STAT3 in MDA-MB-231 and miR-155/ NOS2/NO signaling in both cell lines. Lastly, miR-4317 was found to function as an upstream regulator of CBS and CSE synergistically abrogates the malignancy of BC cells.

          Conclusion

          These findings demonstrate the potential role of H 2S signaling in BC pathogenesis and the potential of its targeting for disease mitigation.

          Related collections

          Most cited references68

          • Record: found
          • Abstract: found
          • Article: not found

          Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

          This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

            Estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. We review the sources and methods used in compiling the national cancer incidence and mortality estimates, and briefly describe the key results by cancer site and in 20 large "areas" of the world. Overall, there were 14.1 million new cases and 8.2 million deaths in 2012. The most commonly diagnosed cancers were lung (1.82 million), breast (1.67 million), and colorectal (1.36 million); the most common causes of cancer death were lung cancer (1.6 million deaths), liver cancer (745,000 deaths), and stomach cancer (723,000 deaths). © 2014 UICC.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Breast Cancer Treatment

              Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Adv Res
                J Adv Res
                Journal of Advanced Research
                Elsevier
                2090-1232
                2090-1224
                16 July 2020
                January 2021
                16 July 2020
                : 27
                : 177-190
                Affiliations
                [a ]Department of Pharmaceutical Biology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Egypt
                [b ]Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA
                [c ]Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Baylor College of Medicine, Houston, TX 77030, USA
                [d ]Texas Children’s Cancer and Hematology Centers, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX 77030, USA
                [e ]Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
                [f ]Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
                [g ]Department of Medical Engineering, Graduate School, Kyung Hee University, Seoul 130-701, Republic of Korea
                [h ]Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
                [i ]Department of General Surgery, Faculty of Medicine, Cairo University, 12613 Cairo, Egypt
                [j ]Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
                [k ]Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Egypt
                [l ]Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA
                [m ]Department of Biochemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Egypt
                Author notes
                [* ]Corresponding author. mohamed.gad@ 123456guc.edu.eg
                Article
                S2090-1232(20)30165-X
                10.1016/j.jare.2020.07.006
                7728592
                33318876
                90bd0454-f045-4f2c-ae7b-1a7b5d89c674
                © 2020 The Authors. Published by Elsevier B.V. on behalf of Cairo University.

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 20 April 2020
                : 6 July 2020
                : 12 July 2020
                Categories
                Article

                breast cancer,hydrogen sulphide,mir-155/nos2/no signaling pathway,pi3k/akt signaling pathway,nitric oxide,mir-4317,natural killer cells,car t cells,bc, breast cancer,car, chimeric antigen receptor,51cr-release, chromium release assay,cd80, cluster of differentiation 80,cd86, cluster of differentiation 86,cbs, cystathionine β-synthase,cse, cystathionine γ-lyase,ctl, cytotoxic t lymphocyte,nos3, endothelial nitric oxide synthase-3,hcc, hepatocellular carcinoma,hla-dr, human leukocytic antigen dr,h2s, hydrogen sulphide,nos2, inducible nitric oxide synthase-2,ifn-γ, interferon gamma,kd, knock down,ldh, lactate dehydrogenase assay,mica/b, mhc class i polypeptide-related sequence a/b,mirna, microrna,nkg2d, natural killer group 2d ,nk, natural killer,no, nitric oxide,ncrnas, non-coding rnas,pd-l1, programmed death-ligand 1,scr-mirnas, scrambled micrornas,scr-sirnas, scrambled sirnas,sirnas, small interfering rnas,tnbc, triple negative breast cancer,tnf-α, tumor necrosis factor-α,ulbp2/5/6, ul16 binding protein 2/5/6,41bbl, 41bb ligand

                Comments

                Comment on this article